As of March 2, all companies listed on the Science and Technology Innovation Board (STAR) have released their 2025 performance data through preliminary earnings reports or forecasts. These projections indicate a total operating revenue of RMB 1.59 trillion, marking a year-on-year increase of 10.3%. Additionally, net profit is expected to reach RMB 59.1 billion, reflecting a substantial year-on-year surge of 28.2%. Over 70% of these companies are poised to experience revenue growth, with 74 companies specifically projected to see increases exceeding 50%.

Fueled by the burgeoning demand from emerging applications, notably in the realm of artificial intelligence, the integrated circuit chip industry continues to sustain its high-growth trajectory. Among the 128 companies that have disclosed their performance figures, the total operating revenue is anticipated to reach RMB 365.1 billion, while net profit is expected to hit RMB 27.9 billion. These figures represent year-on-year increases of 25% and 83%, respectively.

Meanwhile, the innovative drug industry has witnessed a flurry of business development (BD) transactions and has accelerated its global expansion efforts. Collectively, innovative drug companies have reported a net profit of RMB 1.574 billion, a stark contrast to the loss of RMB 6.55 billion recorded during the same period last year. This achievement signifies a remarkable year-on-year turnaround, transitioning from a loss-making position to profitability.